Medifolin (Calcium Folinate)

Calcium folinate provides a reduced folate that enters the folate cycle downstream of the dihydrofolate reductase step. By doing so, it restores folate‑dependent nucleotide synthesis, allowing DNA replication and repair in healthy cells and reducing the toxic effects of antifolate agents such as methotrexate.

The dose of Medifolin is individualized and set by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and concurrent therapies. Healthcare professionals determine the appropriate amount and schedule according to established clinical guidelines.

The safety of calcium folinate in pregnancy and lactation has not been fully established. It should only be used when clearly needed, after a careful risk‑benefit assessment by the treating physician. Breastfeeding mothers should consult their healthcare provider before initiating therapy.

To order Medifolin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Unlike standard folic acid, calcium folinate is a reduced folate that bypasses the dihydrofolate reductase step, making it effective as a rescue agent for antifolate toxicity. Conventional folic acid does not provide the same rapid cellular protection in high‑dose methotrexate settings, where calcium folinate is the preferred choice.

Medifolin should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Maintaining these conditions helps preserve the stability and potency of the oral formulation throughout its shelf life.

Medifolin is supplied as an oral product and is taken by mouth with water. The exact timing relative to other chemotherapy agents, such as methotrexate, is determined by the prescribing clinician to ensure optimal rescue effect and minimize toxicity.

Serious risks include severe allergic reactions (anaphylaxis), bone marrow suppression leading to pancytopenia, significant hepatic dysfunction, acute renal injury, and rare severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for any signs of these events, and treatment should be discontinued if they occur.

Medifolin is contraindicated in patients with known hypersensitivity to calcium folinate or any component of the formulation. It should also be avoided in individuals receiving overlapping antifolate therapy where rescue is not intended, and in patients with severe renal or hepatic impairment unless the prescriber decides the benefits outweigh the risks.